Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The objective of this randomized clinical trial is to test whether administration of live attenuated MMR vaccine (measles mumps rubella; Merck) to eligible adults at highest risk for contracting COVID-19 (healthcare workers, first responders), can induce non-specific trained innate immune leukocytes that can prevent/dampen pathological inflammation and sepsis associated with COVID-19-infection, if exposed.
Description: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of myeloid-derived suppressor cells (MDSCs) Time: 14 days post-vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 30 days post vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 60 days post vaccinationDescription: peripheral blood monocytic MDSCs (M-MDSC) and/or granulocytic MDSCs (G-MDSC) determined by flow cytometry from whole blood samples as percentage/fold increase over baseline
Measure: Induction of MDSCs Time: 12 months post vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 14 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 30 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 60 days post-vaccinationDescription: COVID-19 antibodies (seropositive) or COVID-19 RNA+ as evidence of infection
Measure: COVID-19 infection positive Time: 12 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 14 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 30 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 60 days post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 3 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 4 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 5 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 6 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 7 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 8 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 9 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 10 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 11 months post-vaccinationDescription: Sepsis/lung inflammation, ICU/ventilator usage, in-patient health related co-morbidities and self-reporting mental status (such as general fatigue/stress level)
Measure: Health questionnaire Time: 12 months post-vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports